Ivermectin in Cancer Treatment

Clinical Guidance

• The FDA approves ivermectin only for specific parasitic infections, and it has no proven therapeutic utility for cancer, as stated by the FDA guidelines 1, 2, 3
• Higher doses of ivermectin, potentially needed for anticancer effects, may cause significant adverse effects, according to Clinical Infectious Diseases guidelines 1, 3
• Patients may be attracted to ivermectin due to its low cost and accessibility, particularly in resource-limited settings, as noted by the BMJ 4